1. Home
  2. SRTA vs ARVN Comparison

SRTA vs ARVN Comparison

Compare SRTA & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SRTA

Strata Critical Medical Inc.

HOLD

Current Price

$5.49

Market Cap

530.4M

Sector

N/A

ML Signal

HOLD

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$8.48

Market Cap

600.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SRTA
ARVN
Founded
2014
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
530.4M
600.2M
IPO Year
2019
2018

Fundamental Metrics

Financial Performance
Metric
SRTA
ARVN
Price
$5.49
$8.48
Analyst Decision
Strong Buy
Buy
Analyst Count
4
19
Target Price
$7.81
$15.05
AVG Volume (30 Days)
680.8K
684.7K
Earning Date
05-06-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
242.86
58.84
EPS
N/A
1.70
Revenue
$197,141,000.00
$262,600,000.00
Revenue This Year
$39.27
N/A
Revenue Next Year
$8.52
N/A
P/E Ratio
N/A
$4.88
Revenue Growth
N/A
N/A
52 Week Low
$3.95
$6.97
52 Week High
$6.50
$14.22

Technical Indicators

Market Signals
Indicator
SRTA
ARVN
Relative Strength Index (RSI) 46.16 43.83
Support Level $5.35 $8.37
Resistance Level $5.48 $9.69
Average True Range (ATR) 0.18 0.32
MACD -0.00 -0.09
Stochastic Oscillator 58.89 24.38

Price Performance

Historical Comparison
SRTA
ARVN

About SRTA Strata Critical Medical Inc.

Strata Critical Medical Inc is a time-critical logistics and medical services provider to the U.S. healthcare industry. The group operates one of the nation's air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated 'One Call' solution for donor organ recovery. It includes two segments: Logistics segments which hold, Air Logistics, Ground Logistics and Organ Placement. The second segment is Clinical Segment which includes: Organ Recovery, Normothermic Regional Perfusion (NRP), and Preservation, and Other Clinical Segment which has Cardiac Care, and Other.

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Share on Social Networks: